AstraZeneca’s RESOLUTE phase III trial of Fasenra to treat chronic obstructive pulmonary disease fails to meet primary endpoint: Cambridge, UK Thursday, September 18, 2025, 15:0 ...

Saphnelo, which generated $304 million in sales in the first half of this year, is projected to achieve peak annual sales of ...

Among patients with COPD, at least 50% reported that the disease impacts their daily life and emotional health, according to ...

GlaxoSmithKline (($GSK)) announced an update on their ongoing clinical study. GlaxoSmithKline (GSK) is launching a new clinical study titled A ...

Fathers’ exposure to passive smoking increases the incidence of poor lung health in children, more so with children’s own ...

The disappointing result means that AZ will be unable to follow in the footsteps of GSK, whose IL-5 inhibitor Nucala ...

Biologics targeting type 2 inflammation show strong efficacy in eosinophilic COPD, while non-type 2 approaches remain ...

AstraZeneca (LON:AZN) said on Wednesday its asthma treatment Fasenra did not meet the primary endpoint in a late-stage trial for patients with chronic obstructive pulmonary disease (COPD).

Nektar Therapeutics has presented data of its atopic dermatitis (AD) candidate rezpeg (rezpegaldesleukin), which sent the ...

AstraZeneca's Fasenra misses the primary COPD endpoint while Saphnelo's lupus trial shows significant improvements and ...

Emphysema detected on baseline low-dose chest CT (LDCT) in the lung cancer screening cohort of more than 9,000 asymptomatic ...

Smoke from wildfires outside Baker County is keeping the air quality in the moderate category in Baker City, although ...